DK0666760T3 - Vaccine omfattende en del af konstant domæne af IgE til behandling af IgE-formidlede allergiske reaktioner - Google Patents

Vaccine omfattende en del af konstant domæne af IgE til behandling af IgE-formidlede allergiske reaktioner

Info

Publication number
DK0666760T3
DK0666760T3 DK92920757T DK92920757T DK0666760T3 DK 0666760 T3 DK0666760 T3 DK 0666760T3 DK 92920757 T DK92920757 T DK 92920757T DK 92920757 T DK92920757 T DK 92920757T DK 0666760 T3 DK0666760 T3 DK 0666760T3
Authority
DK
Denmark
Prior art keywords
ige
vaccine
pct
mediated
antibodies
Prior art date
Application number
DK92920757T
Other languages
English (en)
Other versions
DK0666760T4 (da
Inventor
Lars T Hellman
Original Assignee
Lars T Hellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0666760(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lars T Hellman filed Critical Lars T Hellman
Application granted granted Critical
Publication of DK0666760T3 publication Critical patent/DK0666760T3/da
Publication of DK0666760T4 publication Critical patent/DK0666760T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK92920757T 1991-09-26 1992-09-25 Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner DK0666760T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
PCT/SE1992/000673 WO1993005810A1 (en) 1991-09-26 1992-09-25 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS

Publications (2)

Publication Number Publication Date
DK0666760T3 true DK0666760T3 (da) 2000-07-31
DK0666760T4 DK0666760T4 (da) 2008-01-21

Family

ID=20383848

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92920757T DK0666760T4 (da) 1991-09-26 1992-09-25 Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner

Country Status (16)

Country Link
US (1) US5653980A (da)
EP (1) EP0666760B2 (da)
JP (2) JP3583421B2 (da)
KR (1) KR100263359B1 (da)
AT (1) ATE189960T1 (da)
AU (1) AU677573B2 (da)
CA (1) CA2117193C (da)
DE (1) DE69230733T3 (da)
DK (1) DK0666760T4 (da)
ES (1) ES2144424T5 (da)
FI (1) FI107880B (da)
GR (1) GR3033272T3 (da)
HU (1) HU218899B (da)
RU (1) RU2120805C1 (da)
SE (1) SE9102808L (da)
WO (1) WO1993005810A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707083B2 (en) * 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
EP0739214B1 (en) * 1994-01-18 1998-03-18 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
JP3421970B2 (ja) 1996-03-01 2003-06-30 ノバルティス アクチエンゲゼルシャフト ペプチド免疫原
EE9900461A (et) * 1997-04-15 2000-06-15 Farmaceutisk Laboratorium Ferring A/S Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
US7604955B2 (en) * 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
US7425619B2 (en) 2002-08-14 2008-09-16 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP1545607B1 (en) * 2002-09-05 2008-11-19 Resistentia Pharmaceuticals AB Allergy vaccines
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
PL2029173T3 (pl) 2006-06-26 2017-04-28 Macrogenics, Inc. Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
NZ592977A (en) 2008-12-09 2013-01-25 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
ES2665495T3 (es) * 2009-02-25 2018-04-26 Academia Sinica Anticuerpos anti-CemX capaces de unirse a mIgE humana sobre linfocitos B
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104603150A (zh) 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
EP3017048A4 (en) * 2013-07-01 2017-05-17 University of Maryland, College Park Fc coupled compositions and methods of their use
MX2020004469A (es) 2017-10-31 2020-09-07 Oneness Biotech Co Ltd Tratamiento de enfermedades alergicas mediadas por ige.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
EP0617127A1 (en) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
GB8910263D0 (en) * 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment

Also Published As

Publication number Publication date
SE9102808L (sv) 1993-03-27
ES2144424T3 (es) 2000-06-16
JP3583421B2 (ja) 2004-11-04
RU2120805C1 (ru) 1998-10-27
HU218899B (hu) 2000-12-28
DK0666760T4 (da) 2008-01-21
FI941193A (fi) 1994-03-14
AU2676592A (en) 1993-04-27
US5653980A (en) 1997-08-05
DE69230733D1 (de) 2000-04-06
FI941193A0 (fi) 1994-03-14
ES2144424T5 (es) 2008-03-01
EP0666760A1 (en) 1995-08-16
EP0666760B2 (en) 2007-10-10
HUT69782A (en) 1995-09-28
GR3033272T3 (en) 2000-09-29
FI107880B (fi) 2001-10-31
DE69230733T2 (de) 2000-08-03
DE69230733T3 (de) 2008-05-21
HU9400845D0 (en) 1994-06-28
JP2004231663A (ja) 2004-08-19
SE9102808D0 (sv) 1991-09-26
JPH06510768A (ja) 1994-12-01
AU677573B2 (en) 1997-05-01
KR100263359B1 (ko) 2000-08-01
CA2117193C (en) 2008-06-17
WO1993005810A1 (en) 1993-04-01
EP0666760B1 (en) 2000-03-01
ATE189960T1 (de) 2000-03-15
CA2117193A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
DK0666760T3 (da) Vaccine omfattende en del af konstant domæne af IgE til behandling af IgE-formidlede allergiske reaktioner
PT815235E (pt) Vacinas para peste
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0654085T3 (da) Monomere og dimere antistof-fragment-fusionsproteiner
DK1196430T3 (da) Rensning og stabilisering af peptider og proteiner i farmaceutiske midler
Gilhar et al. Transfer of alopecia areata in the human scalp graft/Prkdcscid (SCID) mouse system is characterized by a TH1 response
Uronen-Hansson et al. Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood
KR920700667A (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
Golden et al. Prolonged maintenance interval in Hymenoptera venom immunotherapy
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
Braga et al. Environment and T regulatory cells in allergy
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
MAGRO et al. Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ES2319341T3 (es) Fragmentos tolerogenicos de alergenos naturales.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
King Immunochemical studies of stinging insect venom allergens
Mackay et al. Encyclopedia of medical immunology
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
Ruben Recombinant DNA produced human IL-2, injected in vivo, will substitute for carrier priming of helper function in the South African clawed toad, Xenopus laevis
Lord et al. Laser Raman spectroscopy of biomolecules: Structural studies of ragweed allergen Ra5
CA2327631A1 (en) Inflammatory cytokine secretion inhibition